Based on the measurements of operating efficiency obtained from Aytu BioScience's historical financial statements, Aytu BioScience is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January. At this time, Aytu BioScience's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 44.3 M in 2025, despite the fact that Retained Earnings are likely to grow to (316.9 M). Key indicators impacting Aytu BioScience's financial strength include:
Investors should never underestimate Aytu BioScience's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Aytu BioScience's cash flow, debt, and profitability to make informed and accurate decisions about investing in Aytu BioScience.
Understanding current and past Aytu BioScience Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Aytu BioScience's financial statements are interrelated, with each one affecting the others. For example, an increase in Aytu BioScience's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Aytu BioScience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aytu BioScience. Check Aytu BioScience's Beneish M Score to see the likelihood of Aytu BioScience's management manipulating its earnings.
Aytu BioScience Stock Summary
Aytu BioScience competes with Mitsui Chemicals, Japan Airlines, BioNTech, ICL Israel, and Marti Technologies. Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado. Aytu Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 164 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Aytu BioScience's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Aytu BioScience's current stock value. Our valuation model uses many indicators to compare Aytu BioScience value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aytu BioScience competition to find correlations between indicators driving Aytu BioScience's intrinsic value. More Info.
Aytu BioScience is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, Aytu BioScience's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Aytu BioScience by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Aytu BioScience Systematic Risk
Aytu BioScience's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Aytu BioScience volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Aytu BioScience correlated with the market. If Beta is less than 0 Aytu BioScience generally moves in the opposite direction as compared to the market. If Aytu BioScience Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Aytu BioScience is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Aytu BioScience is generally in the same direction as the market. If Beta > 1 Aytu BioScience moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Aytu BioScience Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aytu BioScience's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Aytu BioScience growth as a starting point in their analysis.
Aytu BioScience December 5, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Aytu BioScience help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Aytu BioScience. We use our internally-developed statistical techniques to arrive at the intrinsic value of Aytu BioScience based on widely used predictive technical indicators. In general, we focus on analyzing Aytu Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aytu BioScience's daily price indicators and compare them against related drivers.
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.